The state of the art in the management of inflammatory bowel disease

Reviews in Gastroenterological Disorders

Volumn 3, Issue 2, 2003, Pages 81-92

  Hanauer, Stephen B ^a   Present, Daniel H ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Crohn's disease; Inflammatory bowel disease; Pharmacotherapy; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; GROWTH HORMONE; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 11; MEDROXYPROGESTERONE ACETATE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NATALIZUMAB; OKT 4; PREDNISONE; PROBIOTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; CROHN DISEASE; DISEASE SEVERITY; DRUG EFFICACY; ENTERITIS; FEMALE; HUMAN; LIFESPAN; MALE; QUALITY OF LIFE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; COLITIS, ULCERATIVE; CROHN DISEASE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; INTESTINAL MUCOSA; LONG-TERM CARE; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SULFASALAZINE; TREATMENT OUTCOME;

EID: 0038382993     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Crohn's & Colitis Foundation of America. Crohn's disease and ulcerative colitis: overview. Available at: http://www.ccfa.org/medcentral/library/basic/facts1.htm. Accessed December 3, 2001.
2. Stein RB, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:297-321.
3. Lashner BA. The cause of inflammatory bowel disease. In: Stein SH, Rood RP, Crohn's & Colitis Foundation of America, eds. Inflammatory Bowel Disease: A Guide for Patients and Their Families. Philadelphia, PA: Lippincott-Raven Publishers; 1999:23-29.
4. Bernstein CN. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep. 2001;3:477-483.
5. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998;93:1867-1872.
6. Maunder R, Toner B, de Rooy E, Moskovitz D. Influence of sex and disease on illness- related concerns in inflammatory bowel disease. Can J Gastroenterol. 1999;13:728-732.
7. Willis JL. Equality in clinical trials: drugs and gender. Your Guide to Women's Health. 3rd ed. FDA Consumer Special Report. September 1997. Available at: http://www.fda.gov/oashi/aids/equal.html. Accessed January 28, 2002.
8. Evelyn B, Toigo T, Banks D, et al. Women's participation in clinical trials and gender-related labeling: a review of new molecular entities approved 1995-1999. Rockville, MD: Office of Special Health Issues, U.S. Food and Drug Administration; June 2001. Available at: http://www.fda.gov/cder/reports/womens_health/women_clin_trials.htm Accessed January 28, 2002.
9. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol. 1997;92:204-211.
10. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993;118:540-549.
11. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000;95:1263-1276.
12. Depo-Medrol® (methylprednisolone acetate injectable suspension, USP). Physicians' Desk Reference®. 56th ed. Montvale, NJ: Medical Economics Co; 2002:2795-2798.
13. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1966;39:1791-1801.
14. Biddle WL, Greenberger NJ, Swan JT, et al. 5-Aminosalicylic acid enemas: effective agents in maintaining remission in left-sided ulcerative colitis. Gastroenterology. 1998;94:1075-1079.
15. Marteau P, Crand J, Foucault M, Rambaud J-C. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomized double blind controlled multicentre study. Gut. 1998;42:195-199.
16. d'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 1997;92:1143-1147.
17. Ardizzone S, Molteni P, Imbesi V, et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol. 1997;25:330-333.
18. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001;120:1323-1329.
19. Lashner BA. Clinical features, laboratory findings, and course of Crohn's disease. In: Stein SH, Rood RP, eds. Inflammatory Bowel Disease: A Guide for Patients and Their Families. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; 2000:305-314.
20. Steinhardt HJ, Loeschke K, Kasper H, et al. European Cooperative Crohn's Disease Study (ECCDS): clinical features and natural history. Digestion. 1985;31:97-108.
21. Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol. 1997;92:559-566.
22. Sachar D, Andrews HA, Farmer RG, et al. Proposed classification of patient subgroups in Crohn's disease. Gastroenterology Int. 1992;5:141-154.
23. Hanauer SB, Sandborn W, Farup PG. Management of Crohn's disease in adults. Am J Gastroenterol. 2001;96:635-643.
24. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology. 1993;104:1293-1301.
25. Targan SR, Hanauer SB, van Deventer SHJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
26. Lichtenstein GR. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease. Inflamm Bowel Dis. 2001;7(suppl 1):S23-S29.
27. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. N Engl J Med. 1994;331:836-841.
28. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994;331:842-845.
29. Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol. 2002;97:915-921.
30. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo-controlled trial of metronidazole in Crohn's disease. Gut. 1991;32:1071-1075.
31. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology. 1980;79:357-365.
32. Flagyl® (metronidazole hydrochloride). Physicians' Desk Reference®. 55th ed. Montvale, NJ: Medical Economics Co; 2001:2967-2969.
33. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1966;91:328-332.
34. Prantera C, Berto E, Scribano ML, Falasco G. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol. 1998;30:602-606.
35. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med. 1995;123:132-142.
36. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med. 1989;111:641-649.
37. Cuffari C. Azathioprine metabolism in inflammatory bowel disease: correlation with efficacy and toxicity. In: Bayless TM, Hanauer SB, eds. Advanced Therapy of Inflammatory Bowel Disease. Hamilton, Ontario: BC Decker; 2001:377-381.
38. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther. 1997;62:464-475.
39. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
40. Present DH. Interaction of 6-mercaptopurine and azathioprine with 5-aminosalicylic acid agents [Letter]. Gastroenterology. 2000;119:276.
41. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment for Crohn's disease. N Engl J Med. 1995;332:292-297.
42. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci. 1994;39:374-380.
43. Neoral® Oral Solution (cyclosporine oral solution, USP) MODIFIED. Physicians' Desk Reference®. 55th ed. Montvale, NJ: Medical Economics Co; 2001:2199-2207.
44. Schaible TF. Important drug warning [letter]. Available at: http://www.fda.gov/medwatch/SAFETY/2001/remicadeTB_deardoc.pdf. Accessed January 21, 2002.
45. Lim WS, Powell RJ, Johnston ID. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346:623-626.
46. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritis. Arthritis Rheum. 2001;44:2862-2869.
47. Deckelbaum L. Important drug warning [letter]. Available at: http://www.fda.gov/medwatch/SAFETY/2001/remicadeTB_deardoc.pdf. Centcor, Inc. Accessed January 22, 2002.
48. Cammà C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465-1473.
49. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine. European Cooperative Crohn's Disease Study VI. Gastroenterology. 2000;118:264-273.
50. Markowitz I, Grancher K, Mandel F, Daum F. 6-Mercaptopurine, (6MP) + prednisone therapy for newly diagnosed pediatric Crohn's disease (CD): a prospective, multicenter, placebo-controlled clinical trial [abstract]. Gastroenterology. 1998;114:1032. Abstract G4227.
51. Hanauer S, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002;359:1541-1549.
52. Sachar DB. Indications for surgery in inflammatory bowel disease: a gastroenterologist's opinion. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia, PA: WB Saunders Company; 2000:611-615.
53. Michelassi F, Fichera A. Indications for surgery in inflammatory bowel disease: the surgeon's perspective. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia, PA: WB Saunders Company; 2000:616-625.
54. Olsen KØ, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology. 2002;122:15-19.
55. Kane S. Adherence issues in management of inflammatory bowel disease. In: Bayless TM, Hanauer SB, eds. Advanced Therapy of Inflammatory Bowel Disease. Hamilton, Ontario: BC Decker, 2001:9-11.
56. Kane SV, Hanauer SB. Medication adherence is associated with improved outcomes in patients with quiescent ulcerative colitis (UC) [abstract]. Gastroenterology. 2000;118:A886. Abstract 4900.
57. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology. 1994;107:117-120.
58. Kane S, Hanauer SB. Predictors of non-compliance with mesalamine in quiescent ulcerative colitis (UC) [abstract]. Gastroenterology. 1999;116:A731.
59. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med. 1991;115:350-355.
60. Hussain FN, Ajjan RA, Kapur K, et al. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther. 2001;15:53-62.
61. Moody GA, Jayanthi V, Probert C, et al. Longterm therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996;8:1179-1183.
62. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000;14:145-153.